Cargando…

Denosumab as a Bridge to Surgery in a Patient with Severe Hypercalcemia Due to Primary Hyperparathyroidism in the Setting of Renal Dysfunction

Detalles Bibliográficos
Autores principales:	Rajan, Remya, Cherian, Kripa Elizabeth, Kapoor, Nitin, Paul, Thomas V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2019
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6540887/ https://www.ncbi.nlm.nih.gov/pubmed/31161118 http://dx.doi.org/10.4103/ijem.IJEM_678_18

Ejemplares similares

Denosumab can be used successfully as a bridge to surgery in patients with severe hypercalcemia due to primary hyperparathyroidism
por: Kuchay, Mohammad Shafi, et al.
Publicado: (2021)

Denosumab for management of severe hypercalcemia in primary hyperparathyroidism
por: Eremkina, Anna, et al.
Publicado: (2020)

Myelofibrosis and Pancytopenia Associated With Primary Hyperparathyroidism
por: Rajan, Remya, et al.
Publicado: (2020)

ODP084 Denosumab as a therapuetic modality in management of primary hyperparathyroidism induced severe hypercalcemia
por: Mangaraj, Swayamsidha, et al.
Publicado: (2022)

Trabecular Bone Score—An Emerging Tool in the Management of Osteoporosis
por: Rajan, Remya, et al.
Publicado: (2020)

An uncommon cause of dysphagia
por: Senthilraja, Manickavasagam, et al.
Publicado: (2019)

Hypercalcemia upon denosumab withdrawal in primary hyperparathyroidism: a case report and literature review
por: Camponovo, C., et al.
Publicado: (2020)

Parathyromatosis Recurrent Hyperparathyroidism and Refractory Hypercalcemia Successfully Managed With Addition of Denosumab: A Case Report
por: Alhammad, Zahrah Abbas, et al.
Publicado: (2021)

A rare cause of familial exogenous Cushing syndrome
por: Rajan, Remya, et al.
Publicado: (2019)

Losartan as a Steroid-Sparing Adjunct in a Patient With Features of Refractory Camurati-Engelmann Disease
por: Agarwal, Khushboo, et al.
Publicado: (2021)

Palliative treatment of uncontrollable hypercalcemia due to parathyrotoxicosis: denosumab as rescue therapy
por: Jumpertz von Schwartzenberg, Reiner, et al.
Publicado: (2015)

Diabetes due to recurrent pancreatitis secondary to hypercalcemia due to primary hyperparathyroidism
por: Chakrabarti, Sumit Kumar, et al.
Publicado: (2013)

Utility of FRAX (fracture risk assessment tool) in primary care and family practice setting in India
por: Cherian, Kripa Elizabeth, et al.
Publicado: (2019)

Lithium-induced Hyperparathyroidism and Hypercalcemia
por: Naramala, Srikanth, et al.
Publicado: (2019)

SAT-499 Denosumab for Treatment of Hypercalcemia in Myelofibrosis
por: Wong, Beatrice, et al.
Publicado: (2019)

Causes of hypercalcemia in renal transplant recipients: persistent hyperparathyroidism and others
por: Moyses-Neto, M., et al.
Publicado: (2021)

Severe Hypercalcemia Due to Primary Hyperparathyroidism and Heterozygous Pathogenic Variant of CYP24A1
por: Liu, Jannel, et al.
Publicado: (2023)

A reversible case of rapidly progressive dementia—Hypercalcemia due to hyperparathyroidism
por: de Oliveira Martins Duarte, Josiana, et al.
Publicado: (2019)

Hypercalcemia due to Co-Occurring Metastatic Breast Cancer and Primary Hyperparathyroidism
por: Khubaib, Mohammad U, et al.
Publicado: (2021)

Efficacy of antiresorptive agents bisphosphonates and denosumab in mitigating hypercalcemia and bone loss in primary hyperparathyroidism: A systematic review and meta-analysis
por: Rajput, Swati, et al.
Publicado: (2023)

Concurrent Primary Hyperparathyroidism and Sarcoidosis in a Patient With Severe Hypercalcemia
por: Ayyad, Mohammed, et al.
Publicado: (2023)

Correction to “Severe Hypercalcemia Due to Primary Hyperparathyroidism and Heterozygous Pathogenic Variant of CYP24A1”
Publicado: (2023)

Management of Primary Hyperparathyroidism With Severe Hypercalcemia During the COVID-19 Pandemic
por: Alfadhli, Eman M.
Publicado: (2021)

Severe hypercalcemia due to teriparatide
por: Karatoprak, Cumali, et al.
Publicado: (2012)

Hypercalcemia following discontinuation of denosumab therapy: A systematic review
por: Horiuchi, Keisuke, et al.
Publicado: (2021)

Rebound Hypercalcemia After Denosumab Therapy in a Child With Cherubism
por: Litao, Melissa Kaori S, et al.
Publicado: (2021)

Denosumab as the Treatment of Recalcitrant Tuberculous Pleural Effusion-Associated Hypercalcemia
por: Abd Jalil, Afdhal Afiq, et al.
Publicado: (2021)

SUN-514 Severe Hypophosphatemia and Worsening Secondary Hyperparathyroidism Following Treatment with Denosumab
por: Adepoju, Yewande, et al.
Publicado: (2019)

SAT228 Denosumab Associated Severe Hypocalcemia Due To Vitamin D Deficiency In A Patient With Undiagnosed Primary Hyperparathyroidism
por: Reddy Bendaram, Snigdha, et al.
Publicado: (2023)

SAT-359 Hypercalcemia - Is This Sarcoidosis, Hyperparathyroidism, or Both?
por: Veeramachaneni, Ravali, et al.
Publicado: (2020)

Severely Deranged Lipid Profile: Caught Unawares
por: Jose, Antresa, et al.
Publicado: (2022)

Severe Idiopathic Osteoporosis in a Premenopausal Woman: A Case for Dual Therapy
por: Soumya, Sudarsanababu Lalitha, et al.
Publicado: (2020)

Vitamin A and Hydrochlorothiazide Causing Severe Hypercalcemia in a Patient With Primary Hyperparathyroidism
por: Varghese, Ron T., et al.
Publicado: (2019)

Symptomatic Hypercalcemia in Patients with Primary Hyperparathyroidism Is Associated with Severity of Disease, Polypharmacy, and Comorbidity
por: Aresta, C., et al.
Publicado: (2019)

PSAT214 Management of Hyperparathyroidism Associated with Severe Hypercalcemia Presenting During Labour
por: Mendez, Juan Vasquez, et al.
Publicado: (2022)

SUN-513 Parathyromatosis: A Case of Stubborn Hypercalcemia Treated with Denosumab
por: Ventura, Kenilia, et al.
Publicado: (2019)

Humoral Hypercalcemia in a Patient with Cholangiocellular Carcinoma – Effective Therapy with Denosumab
por: Harsch, Igor Alexander, et al.
Publicado: (2019)

Denosumab-Induced Rebound Hypercalcemia Treated With Bisphosphonates in a Pediatric Patient
por: Gandolfi, Anne, et al.
Publicado: (2023)

THU472 Novel And Multifactorial Case Of Severe Hypercalcemia Due To Primary Hyperparathyroidism And Heterozygous Mutation Of CYP24A1
por: Liu, Jannel, et al.
Publicado: (2023)

Glucocorticoid-induced Osteoporosis
por: Cherian, Kripa Elizabeth, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_6jtm9si8k6egacpaou8epe682g